Salud financiera de hoja de balance de Eledon Pharmaceuticals
Salud financiera controles de criterios 6/6
Eledon Pharmaceuticals tiene un patrimonio de los accionistas total de $74.8M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $80.8M y $6.0M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$42.86m |
| Patrimonio | US$74.82m |
| Total pasivo | US$6.00m |
| Activos totales | US$80.82m |
Actualizaciones recientes sobre salud financiera
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Mar 22
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Dec 05Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Aug 10We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Apr 27Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation
Jan 05Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?
Aug 31Recent updates
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Mar 22Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Dec 05Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Aug 10We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Apr 27Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation
Jan 05Eledon adds 10% as FDA clears clinical trial for kidney disease candidate
Sep 06Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?
Aug 31Eledon gets FDA nod to start trial of organ rejection preventing therapy
Aug 01Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients
Jul 18Eledon gives update on development strategy for AT-1501 in renal transplantation
Apr 26Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans
Apr 14What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?
Feb 21Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation
Dec 30
Novus Therapeutics (NVUS) Investor Presentation - Slideshow
Dec 18Novus Therapeutics EPS misses by $3.76
Nov 16Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease
Nov 02Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($48.0M) de ELDN superan a sus pasivos a corto plazo ($4.2M).
Pasivo a largo plazo: Los activos a corto plazo de ELDN ($48.0M) superan a sus pasivos a largo plazo ($1.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ELDN está libre de deudas.
Reducción de la deuda: ELDN no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ELDN tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ELDN dispone de suficiente cash runway para 1.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 22.5% cada año.